Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck
BACKGROUND: Because of the structural and biochemical similarities between the antitumor p53 and p73 proteins, the authors hypothesized that individuals who carry high-risk genotypes of p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms have a higher risk of developing second primary malignancy (SPM) after index squamous cell carcinoma of the head and neck (SCCHN). METHODS: A cohort of 1269 patients with index cases of SCCHN was recruited between May 1995 and January 2007 at The University of Texas MD Anderson Cancer Center and followed for SPM development. Patients were genotyped for p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms. A log-rank test and Cox proportional hazard models were used to compare SPM-free survival and SPM risk among different risk groups with the combined risk genotypes of the 2 polymorphisms. RESULTS: The data demonstrated that patients with p53 WP + PP and p73 GC/GC genotypes had a worse SPM-free survival and an increased SPM risk compared with the corresponding p53 WW and p73 GC/AT + AT/AT genotypes. After combining the 2 polymorphisms, a borderline significantly or significantly reduced SPM-free survival and increased SPM risk were observed in the mediumrisk group (p53 WW and p73 GC/GC or p53 P carriers and p73 AT carriers) and high-risk group (p53 P carriers and p73 GC/GC) compared with low-risk group (p53 WW and p73 AT carriers), respectively. CONCLUSIONS: The results suggest an increased risk of SPM after index SCCHN with both p53 and p73 polymorphisms individually and in combination. Cancer 2012; 118: 485-92. (C) 2011 American Cancer Society.
基金:
Research Training Award; American Laryngological, Rhinological, and Otological Society; University of Texas MD Anderson Cancer Center; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K-12 88084]; National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01 ES-11740]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA135679-01, CA133099-01A1]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K07CA133099, R01CA131274, R03CA135679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES011740] Funding Source: NIH RePORTER
第一作者机构:[1]Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA[2]Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol & Head & Neck Surg, Beijing, Peoples R China
通讯作者:
通讯机构:[1]Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA[3]Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA[*1]Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Unit 1445,1515 Holcombe Blvd, Houston, TX 77030 USA
推荐引用方式(GB/T 7714):
Zhang Yang,Sturgis Erich M.,Huang Zhigang,et al.Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck[J].CANCER.2012,118(2):485-492.doi:10.1002/cncr.26222.
APA:
Zhang, Yang,Sturgis, Erich M.,Huang, Zhigang,Zafereo, Mark E.,Wei, Qingyi&Li, Guojun.(2012).Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck.CANCER,118,(2)
MLA:
Zhang, Yang,et al."Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck".CANCER 118..2(2012):485-492